Literature DB >> 17001621

A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.

Stian Knappskog1, Jürgen Geisler, Thomas Arnesen, Johan R Lillehaug, Per E Lønning.   

Abstract

Linkage to the CDKN2A locus has been demonstrated in approximately 50% of families with hereditary malignant melanoma but only a subgroup of these harbor identified mutations. We here report a Norwegian melanoma-prone family with a novel large germline deletion removing 13707 bps of the CDKN2A gene, including exon 1alpha and approximately half of exon 2. Our finding is the first reported large CDKN2A germline deletion with a breakpoint located within an exon. This type of deletion is not detectable through the direct exon sequencing and may also escape identification by use of multiplex ligation-dependent probe amplification (MLPA) analysis. Here, the defect was identified through detection of a truncated p14(ARF) mRNA and loss of p16(INK4a) mRNA expression from the affected allele. Our finding suggests that atypical, large deletions in the CDKN2A gene may explain linkage to the 9p21 chromosome band without identified gene mutations among melanoma-prone families. Thus, it illustrates the need to include p14(ARF)- and p16(INK4a) transcript analysis when searching for unknown mutations within the CDKN2A locus in melanoma-prone families. Similar deletions with atypical breakpoints may affect other genes involved in cancer disposition, and the need to examine gene transcripts in high-risk families with no mutation identified through conventional testing should be considered. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001621     DOI: 10.1002/gcc.20379

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q.

Authors:  Craig Teerlink; James Farnham; Kristina Allen-Brady; Nicola J Camp; Alun Thomas; Sancy Leachman; Lisa Cannon-Albright
Journal:  Hum Genet       Date:  2011-06-26       Impact factor: 4.132

2.  Germline hemizygous deletion of CDKN2A-CDKN2B locus in a patient presenting with Li-Fraumeni syndrome.

Authors:  Sock Hoai Chan; Weng Khong Lim; Scott T Michalski; Jing Quan Lim; Nur Diana Binte Ishak; Marie Met-Domestici; Cedric Ng Chuan Young; Karen Vikstrom; Edward D Esplin; Jennifer Fulbright; Mei Kim Ang; Joseph Wee; Kesavan Sittampalam; Mohamad Farid; Stephen E Lincoln; Koji Itahana; Syafiq Abdullah; Bin Tean Teh; Joanne Ngeow
Journal:  NPJ Genom Med       Date:  2016-06-01       Impact factor: 8.617

3.  Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Authors:  Stian Knappskog; Elisabet O Berge; Ranjan Chrisanthar; Stephanie Geisler; Vidar Staalesen; Beryl Leirvaag; Synnøve Yndestad; Elise de Faveri; Bård O Karlsen; David C Wedge; Lars A Akslen; Peer K Lilleng; Erik Løkkevik; Steinar Lundgren; Bjørn Østenstad; Terje Risberg; Ingvild Mjaaland; Turid Aas; Per E Lønning
Journal:  Mol Oncol       Date:  2015-05-08       Impact factor: 6.603

Review 4.  Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.

Authors:  Zizhen Ming; Su Yin Lim; Helen Rizos
Journal:  Biomolecules       Date:  2020-10-15

Review 5.  CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

Authors:  Sock Hoai Chan; Jianbang Chiang; Joanne Ngeow
Journal:  Hered Cancer Clin Pract       Date:  2021-03-25       Impact factor: 2.857

6.  Germline CDH1 deletions in hereditary diffuse gastric cancer families.

Authors:  Carla Oliveira; Janine Senz; Pardeep Kaurah; Hugo Pinheiro; Remo Sanges; Anne Haegert; Giovanni Corso; Jan Schouten; Rebecca Fitzgerald; Holger Vogelsang; Gisela Keller; Sarah Dwerryhouse; Donna Grimmer; Suet-Feung Chin; Han-Kwang Yang; Charles E Jackson; Raquel Seruca; Franco Roviello; Elia Stupka; Carlos Caldas; David Huntsman
Journal:  Hum Mol Genet       Date:  2009-01-24       Impact factor: 6.150

7.  The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Authors:  F Lesueur; M de Lichy; M Barrois; G Durand; J Bombled; M-F Avril; A Chompret; F Boitier; G M Lenoir; B Bressac-de Paillerets; Monique Baccard; Bertrand Bachollet; Pascaline Berthet; Valérie Bonadona; Jean-Marie Bonnetblanc; Olivier Caron; Jacqueline Chevrant-Breton; Jean-François Cuny; Stéphane Dalle; Michèle Delaunay; Liliane Demange; Julie De Quatrebarbes; Jean-François Doré; Marc Frénay; Jean-Pierre Fricker; Marion Gauthier-Villars; Paul Gesta; Sophie Giraud; Philippe Gorry; Florent Grange; Andrew Green; Laetitia Huiart; Nicolas Janin; Pascal Joly; Delphine Kérob; Christine Lasset; Dominique Leroux; Jean-Marc Limacher; Michel Longy; Sandrine Mansard; Karine Marrou; Tanguy Martin-Denavit; Christine Mateus; Eve Maubec; Laurence Olivier-Faivre; Vincent Orlandini; Pascal Pujol; Bruno Sassolas; Dominique Stoppa-Lyonnet; Luc Thomas; Pierre Vabres; Laurence Venat; Ewa Wierzbicka; Hélène Zattara
Journal:  Br J Cancer       Date:  2008-07-08       Impact factor: 7.640

8.  A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.

Authors:  Simona Frigerio; Vittoria Disciglio; Siranoush Manoukian; Bernard Peissel; Gabriella Della Torre; Andrea Maurichi; Paola Collini; Barbara Pasini; Giacomo Gotti; Andrea Ferrari; Licia Rivoltini; Maura Massimino; Monica Rodolfo
Journal:  BMC Med Genet       Date:  2014-05-17       Impact factor: 2.103

9.  Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.

Authors:  Ulrika Andersson; Carl Wibom; Kristina Cederquist; Steina Aradottir; Ake Borg; Georgina N Armstrong; Sanjay Shete; Ching C Lau; Matthew N Bainbridge; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Richard S Houlston; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel H Lachance; Margaret Wrensch; Faith G Davis; Ryan Merrell; Christoffer Johansen; Siegal Sadetzki; Melissa L Bondy; Beatrice S Melin
Journal:  Neuro Oncol       Date:  2014-04-09       Impact factor: 12.300

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.